JP6691477B2 - クロストリジウム・ディフィシル（ｃ．ｄｉｆｆｉｃｉｌｅ）に対して免疫する組成物及び方法 - Google Patents
クロストリジウム・ディフィシル（ｃ．ｄｉｆｆｉｃｉｌｅ）に対して免疫する組成物及び方法 Download PDFInfo
- Publication number
- JP6691477B2 JP6691477B2 JP2016519675A JP2016519675A JP6691477B2 JP 6691477 B2 JP6691477 B2 JP 6691477B2 JP 2016519675 A JP2016519675 A JP 2016519675A JP 2016519675 A JP2016519675 A JP 2016519675A JP 6691477 B2 JP6691477 B2 JP 6691477B2
- Authority
- JP
- Japan
- Prior art keywords
- days
- composition
- toxin
- difficile
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361835246P | 2013-06-14 | 2013-06-14 | |
| US61/835,246 | 2013-06-14 | ||
| PCT/US2014/042298 WO2014201346A1 (en) | 2013-06-14 | 2014-06-13 | Compositions and methods of immunizing against c. difficile |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016521754A JP2016521754A (ja) | 2016-07-25 |
| JP2016521754A5 JP2016521754A5 (enExample) | 2017-07-27 |
| JP6691477B2 true JP6691477B2 (ja) | 2020-04-28 |
Family
ID=51168412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016519675A Active JP6691477B2 (ja) | 2013-06-14 | 2014-06-13 | クロストリジウム・ディフィシル（ｃ．ｄｉｆｆｉｃｉｌｅ）に対して免疫する組成物及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US9730994B2 (enExample) |
| EP (1) | EP3007724B1 (enExample) |
| JP (1) | JP6691477B2 (enExample) |
| KR (1) | KR20160020543A (enExample) |
| CN (1) | CN105611942A (enExample) |
| AU (1) | AU2014277981B2 (enExample) |
| BR (1) | BR112015031088A2 (enExample) |
| CA (1) | CA2915279A1 (enExample) |
| MX (1) | MX2015017257A (enExample) |
| SG (1) | SG11201510166YA (enExample) |
| TW (1) | TWI648063B (enExample) |
| WO (1) | WO2014201346A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3505531T1 (sl) | 2011-04-22 | 2024-02-29 | Wyeth Llc | Kompozicije, povezane z mutantnim toksinom clostridium difficile in njegovimii metodami |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| MX2015017257A (es) | 2013-06-14 | 2016-11-11 | Sanofi Pasteur Inc | Composiciones y metodos de inmunizar contra clostridium difficile. |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| AU2018343217B2 (en) * | 2017-09-28 | 2024-11-07 | Pfizer Inc. | Compositions and methods for eliciting an immune response against Clostridium difficile |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5071759A (en) | 1986-05-30 | 1991-12-10 | The United States Of America As Represented By The Secretary Of The Army | Hybridoma cell lines and monoclonal antibodies to clostridum difficile toxins A and B |
| US6969520B2 (en) * | 1997-10-20 | 2005-11-29 | Acambis Inc. | Active immunization against clostridium difficile disease |
| US6214341B1 (en) | 1997-10-20 | 2001-04-10 | Oravax | Passive immunization against Clostridium difficile disease |
| BRPI0816790A8 (pt) * | 2007-09-14 | 2017-05-16 | Sanofi Pasteur Biologics Co | Composições farmacêuticas contendo toxóides a e b de clostridium difficile |
| GB0921288D0 (en) | 2009-12-04 | 2010-01-20 | Health Prot Agency | Therapies for preventing or suppressing clostridium difficile infection |
| SI3505531T1 (sl) | 2011-04-22 | 2024-02-29 | Wyeth Llc | Kompozicije, povezane z mutantnim toksinom clostridium difficile in njegovimii metodami |
| AR089797A1 (es) | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
| GB201206070D0 (en) | 2012-04-04 | 2012-05-16 | Health Prot Agency | Clostridium difficile antigens |
| JP2016516721A (ja) * | 2013-03-15 | 2016-06-09 | サノフィ パストゥール インコーポレイテッド | トキソイド、組成物および関連方法 |
| CN105308066A (zh) * | 2013-03-15 | 2016-02-03 | 圣诺菲·帕斯图尔公司 | 类毒素、组合物和相关的方法 |
| MX2015017257A (es) | 2013-06-14 | 2016-11-11 | Sanofi Pasteur Inc | Composiciones y metodos de inmunizar contra clostridium difficile. |
-
2014
- 2014-06-13 MX MX2015017257A patent/MX2015017257A/es unknown
- 2014-06-13 WO PCT/US2014/042298 patent/WO2014201346A1/en not_active Ceased
- 2014-06-13 AU AU2014277981A patent/AU2014277981B2/en not_active Ceased
- 2014-06-13 JP JP2016519675A patent/JP6691477B2/ja active Active
- 2014-06-13 KR KR1020167001130A patent/KR20160020543A/ko not_active Ceased
- 2014-06-13 CA CA2915279A patent/CA2915279A1/en not_active Abandoned
- 2014-06-13 BR BR112015031088A patent/BR112015031088A2/pt not_active Application Discontinuation
- 2014-06-13 SG SG11201510166YA patent/SG11201510166YA/en unknown
- 2014-06-13 US US14/897,870 patent/US9730994B2/en active Active
- 2014-06-13 CN CN201480044768.7A patent/CN105611942A/zh active Pending
- 2014-06-13 EP EP14737429.2A patent/EP3007724B1/en active Active
- 2014-06-16 TW TW103120772A patent/TWI648063B/zh not_active IP Right Cessation
-
2017
- 2017-07-10 US US15/645,057 patent/US20170304423A1/en not_active Abandoned
-
2019
- 2019-10-21 US US16/658,278 patent/US20200113991A1/en not_active Abandoned
-
2021
- 2021-01-08 US US17/144,486 patent/US11419930B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20210145956A1 (en) | 2021-05-20 |
| US11419930B2 (en) | 2022-08-23 |
| EP3007724A1 (en) | 2016-04-20 |
| AU2014277981A1 (en) | 2016-01-07 |
| CA2915279A1 (en) | 2014-12-18 |
| TWI648063B (zh) | 2019-01-21 |
| CN105611942A (zh) | 2016-05-25 |
| TW201536314A (zh) | 2015-10-01 |
| US20160120968A1 (en) | 2016-05-05 |
| AU2014277981B2 (en) | 2019-06-20 |
| US20200113991A1 (en) | 2020-04-16 |
| JP2016521754A (ja) | 2016-07-25 |
| EP3007724B1 (en) | 2023-07-05 |
| KR20160020543A (ko) | 2016-02-23 |
| WO2014201346A1 (en) | 2014-12-18 |
| BR112015031088A2 (pt) | 2017-07-25 |
| US20170304423A1 (en) | 2017-10-26 |
| US9730994B2 (en) | 2017-08-15 |
| SG11201510166YA (en) | 2016-01-28 |
| MX2015017257A (es) | 2016-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11419930B2 (en) | Compositions and methods for immunizing against C. difficile | |
| De Bernardis et al. | A virosomal vaccine against candidal vaginitis: immunogenicity, efficacy and safety profile in animal models | |
| US11680087B2 (en) | Neisseria meningitidis compositions and methods thereof | |
| US20210085773A1 (en) | Neisseria meningitidis compositions and methods thereof | |
| US20250312432A1 (en) | Compositions and methods for eliciting an immune response against clostridium difficile | |
| RU2559782C2 (ru) | Набор для детекции спор, происходящих из микобактерий | |
| Ribeiro et al. | PLGA-dendron nanoparticles enhance immunogenicity but not lethal antibody production of a DNA vaccine against anthrax in mice | |
| WO2018006939A1 (en) | Inactivated tuberculosis vaccine | |
| JP2021503509A (ja) | 哺乳動物における趾皮膚炎に使用されるワクチン組成物 | |
| US20220313816A1 (en) | Compositions and methods for antibody-as-adjuvant vaccines and therapeutics | |
| Sanders | Investigation of the potential of PorA and FetA as meningococcal vaccine components |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170613 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170613 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180227 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180528 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180726 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180827 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190123 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190423 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190624 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191127 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200311 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200410 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6691477 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |